

UNITED STATES DISTRICT COURT
EASTERN DISTRICT OF LOUISIANA

In Re: TAXOTERE (DOCETAXEL)
PRODUCTS LIABILITY
LITIGATION

MDL NO. 2740
SECTION “N” (5)

THIS DOCUMENT RELATES TO:
ALL CASES

JOINT REPORT NO. 7 OF LIAISON COUNSEL
(Status Conference, December 15, 2017)

NOW INTO COURT come Plaintiffs’ Co-Liaison Counsel (“PLC”) and Defendants’ Liaison Counsel (“DLC”), who respectfully submit this Joint Report No. 7 of Liaison Counsel.

1. REPORT OF CLAIMS AND CASE INVENTORY

On October 4, 2016, the Judicial Panel on Multidistrict Litigation (“JPML”) transferred 28 civil action(s) to the United States District Court for the Eastern District of Louisiana for coordinated or consolidated pretrial proceedings pursuant to 28 U.S.C. § 1407. *See In re Taxotere (Docetaxel) Prod. Liab. Litig.*, No. MDL 2740, 2016 WL 5845996 (U.S. Jud. Pan. Mult. Lit. Oct. 4, 2016). Since that time, excluding voluntary dismissals, additional actions have been transferred to the Eastern District of Louisiana pursuant to Conditional Transfer Orders of the JPML. As of December 12, 2017, excluding voluntary dismissals, there are approximately 7,500 cases pending in the MDL before the Honorable Kurt D. Engelhardt.

2. FEDERAL/STATE COORDINATION

Related state court proceedings have been filed in California, Missouri, New Jersey, and Delaware. Most of these state court proceedings were removed to federal court. The Court ruled on remand motions on August 30, 2017. (Rec. Doc. 781). The Court received supplemental briefing on whether two California multi-plaintiff cases could be severed prior to

remand and that issue remains pending before the Court. New information has been presented to sanofi regarding McKesson's role in distributing docetaxel as to some plaintiffs in the two multi-plaintiff cases pending in the MDL---*Ernyes-Kofler* (case no. 2:17-cv-03867) and *McCallister* (case no. 2:17-cv-02356). Both cases were subject to Plaintiffs' Motion to Remand. Counsel for sanofi requested the Court to withhold ruling on the remand/severance issue in these two cases to allow them time to collect the necessary declarations and complete their investigation, and submit this information to the Court. Plaintiffs request that the Court allow counsel in these two cases a reasonable period of time to submit a reply after receiving sanofi's additional briefing.

The parties continue to coordinate and communicate with all counsel and advise them of the status conference call in number (listen only). The parties also continue to make efforts to identify the relevant state court judge(s) of the MDL and the Court's willingness to cooperate with the state court judges for the purposes of coordinating discovery and other pretrial proceedings, and to provide the call-in number for the status conferences, should they wish to join. The Court has been in communication with the Honorable Judge Vivian Medinilla of Delaware as Judge Medinilla has many cases in her court that were remanded from this Court.

Three California cases in different counties have been assigned at least one Taxotere case. Federal-state Liaison Counsel provided the Court with the names and contact information for these 3 state court judges.

3. PRETRIAL ORDERS

A listing of all Pretrial Orders is attached to this Joint Report as Appendix A.7.

The Court has issued the following important Pretrial Orders (sometimes "PTO")

since the October 27, 2017 Status Conference:

- a. **Pretrial Order No. 68** (Rec. Doc. 1085) entered November 9, 2017 setting Deadlines following October 27, 2017 meeting with Steering Committees regarding ESI Guidance.
- b. **Pretrial Order No. 69** (Rec. Doc. 1095) entered November 14, 2017 setting deadline for submission of applications for Court appointed positions with MDL 2740 as November 15, 2017.
- c. **Pretrial Order No. 70** (Rec. Doc. 1137) entered November 21, 2017 regarding contact with physicians.
- d. **Pretrial Order No. 71** (Rec. Doc 1306) entered December 15, 2017 regarding Plaintiffs' Responsibilities Relevant to ESI.
- e. **Pretrial Order No. 72** (Rec. Doc. 1462) entered January 4, 2018 regarding dismissal of the French Sanofi Defendants per Stipulation.
- f. **Pretrial Order No. 73** (Rec. Doc. 1463) entered January 4, 2018 regarding Revised Exemplar Short Form Complaint.
- g. **Pretrial Order No. 74** (Rec. Doc. 1470) entered January 4, 2018 regarding Procedures for Withdrawal of Counsel.
- h. **Pretrial Order No. 75** (Rec. Doc. 1507) entered January 12, 2018 regarding Reappointment of Counsel in MDL 2740.

4. **CASE MANAGEMENT ORDERS**

A listing of all Case Management Orders is attached to this Joint Report as Appendix

B.7. The Court has issued the following Case Management Orders since the October 27, 2017 Status Conference:

- a. **Case Management Order No. 8A** (Rec. Doc. 1099) entered on November 14, 2017 superseding CMO No. 8 for setting the trial scheduling order for the second bellwether trial on January 28, 2019.
- b. **Case Management Order No. 9** (Rec. Doc. 1100) entered November 15, 2017 setting the Deposition Protocol.

- c. **Case Management Order No. 10** (Rec. Doc. 1168) entered December 6, 2017 setting forth the Protocol for Phase I Discovery of Cases Identified in CMO No. 8A.
- d. **Case Management Order No. 11** (Rec. Doc. 1430) entered December 27, 2017 extending Certain Deadlines in CMO No. 3.
- e. **Case Management Order No. 12** (Rec. Doc. 1506) entered January 12, 2018 setting forth a Process for Obtaining Product Identification for Multi-Defendant Cases.

The parties will meet and confer and submit Case Management Orders for the third, fourth and fifth trial dates in 2019.

5. COUNSEL CONTACT INFORMATION FORM

All counsel in the MDL are required to complete the Counsel Contact Information Form (available as a fillable PDF on the Court's MDL 2740 website) attached to PTO No. 7 (Rec. Doc. 155), and forward it to PLC at taxotere@ bkc-law.com. This information must be kept current by each counsel and will be relied upon throughout the litigation. PLC provides a copy of all Counsel Contact Forms to Jacob Woody at BrownGreer. BrownGreer will rely on the information included in the Counsel Contact Form to serve all pleadings.

6. MASTER COMPLAINT AND SHORT FORM COMPLAINT

The Master Long Form Complaint was filed on March 31, 2017. (Rec. Doc. 312). On April 16, 2017, the Court issued Pretrial Order No. 37 (Rec. Doc. 318), attaching the exemplar Short Form Complaint (Rec. Doc. 318-1) as Exhibit A to the Order to be used by counsel when filing complaints as provided by Pretrial Order No. 37 (Rec. Doc. 318) and Pretrial Order No. 15 (Rec. Doc. 230). On April 18, 2017, the Court issued Pretrial Order No.

41 (Rec. Doc. 331), which granted Plaintiffs' Co-Liaison Counsel's Consent Motion to Amend Exhibit A (Rec. Doc. 318-1) to Pretrial Order No. 37 (Rec. Doc. 318) to allow for the names of Plaintiff(s) and Defendant(s) to be inserted into the case caption of the exemplar Short Form Complaint. Thus, Pretrial Order No. 41 (Rec. Doc. 331) ordered that Exhibit A to Pretrial Order No. 37 (Rec. Doc. 318-1) be amended to reflect the updated version of the exemplar Short Form Complaint.

Due to issues with the proper naming of some Defendants, the parties filed a Stipulation Concerning Amendments to Plaintiffs' Master Long Form Complaint, Exemplar Short Form Complaint and Plaintiff Fact Sheet (Rec. Doc. 642). Thereafter, Plaintiffs, through the Plaintiffs' Steering Committee, filed an Unopposed Motion for Leave to File First Amended Master Long Form Complaint, for Substitution of Revised Plaintiff Fact Sheet, and for Substitution of Revised Exemplar Short Form Complaint (Rec. Doc. 613), requesting that the Court replace the current exemplar Short Form Complaint (Rec. Doc. 318-1), or Exhibit A to Pretrial Order No. 37, with the revised exemplar Short Form Complaint attached as Exhibit C (Rec. Doc. 673-3) to Plaintiffs' motion. The Court then entered Pretrial Order No. 55 (Rec. Doc. 688), which granted Plaintiffs' motion. Thus, Plaintiffs' First Amended Master Long Form Complaint was entered into the record (Rec. Doc. 689), and the revised exemplar Short Form Complaint, which was attached as Exhibit C (Rec. Doc. 673-3) to Plaintiffs motion, was substituted in place of the exemplar Short Form Complaint (Rec. Doc. 318-1) found as Exhibit A to Pretrial Order No. 37 (Rec. Doc. 318).

On August 30, 2017, the Court granted Defendants' Motion to Dismiss Plaintiffs' Master Long Form Complaint (Rec. Doc. 489) as to Count II and Count VIII of Plaintiffs' Master Long Form Complaint. *See* Pretrial Order No. 61 (Rec. Doc. 877). Moreover, under

the Stipulation of Terms Related to Defendants, Sanofi and Aventis Pharma S.A. (Rec. Doc. 1072) (“French Defendants”) are dismissed without prejudice from all MDL cases. (See Section 10 below). Thus, on December 14, 2017, Defendants, through Defendants’ Liaison Counsel filed Defendants’ Consent Motion for Substitution of Second Amended Exemplar Short Form Complaint (Rec. Doc. 1254), requesting that the Court grant the motion and replace the revised exemplar Short Form Complaint, which can be found as Exhibit A (Rec. Doc. 318-1) to Pretrial Order No. 37 (Rec. Doc. 318), with the proposed Second Amended Exemplar Short Form Complaint, which was attached as an Exhibit (Rec. Doc. 1254-2) to the motion.

On January 4, 2018, the Court entered Pretrial Order No. 73 (Rec. Doc. 1463), granting Defendants’ Consent Motion for Substitution of Second Amended Exemplar Short Form Complaint (Rec. Doc. 1254) and attaching the approved version of the Short Form Complaint (Rec. Doc. 1463-1), which indicates it is the effective version of the form as of December 21, 2017.¹ Moreover, the Court replaced the revised exemplar Short Form Complaint, which can be found as Exhibit A (Rec. Doc. 318-1) to Pretrial Order No. 37 (Rec. Doc. 318), with the approved Short Form Complaint. Plaintiffs’ Liaison Counsel cautions all Plaintiffs that this update of the exemplar Short Form Complaint does not require that an individual plaintiff who previously filed a Short Form Complaint on an old version of the

¹ While the version of the Short Form Complaint adopted by this Court is substantively the same as the proposed Second Amended Short Form Complaint (Rec. Doc. 1254-2) submitted by counsel, the Court has made changes to the title of the Short Form Complaint. The Court-approved version of the Short Form Complaint that is attached to Pretrial Order No. 73 as Exhibit A (Rec. Doc. 1463-1) and also found as Exhibit A (Rec. Doc. 318-1) is entitled “Short Form Complaint (Effective as of December 21, 2017)” for purposes of clarity. Furthermore, the Court has inserted a footnote after this title to explain that this version of the Short Form Complaint shall supersede all other versions and should be the only version used for future filings.

form file a new Short Form Complaint on the updated version of the form.

However, if it is necessary for counsel to file a new member case or amend a previously filed Short Form Complaint, Counsel should ONLY use the Court-approved Short Form Complaint effective as of December 21, 2017, which is available on the Court's MDL 2740 website under the "Forms" tab or through MDL Centrality. Counsel are cautioned not to use old versions of the Short Form Complaint that have come from the record or elsewhere, or their filing will be marked "Deficient" by the Clerk's Office. Counsel are further advised to make reference to the Master Long Form Complaint when completing the Short Form Complaint.

Should any Plaintiff wish to file an Amended Complaint, the Court's Local Rule 7.6² requires that before filing any motion for leave to amend pleadings, Plaintiff must attempt to obtain the consent for the filing and granting of the motion from all parties having an interest to oppose. Plaintiffs' counsel must email each request³ for consent to Defendants' Liaison Counsel, Douglas Moore, dmoore@irwinllc.com, and John Olinde, Olinde@chaffe.com, who will forward the request to the appropriate attorneys for a response. If consent is obtained, the motion need not be assigned a submission date, but must be accompanied by a proposed order and include a certification by counsel for Plaintiff of the consent of opposing counsel. If consent is not granted, the motion for leave to amend the pleadings must be filed as an opposed motion.

Additionally, should any Plaintiff's counsel use the Short Form Complaint as an amending complaint, and not include all Defendants named in any earlier complaint, the Clerk's office will close that Plaintiff's claims against the Defendant(s) who is (are) not named.

Moreover, attention must be paid to amendments entailing voluntary dismissal of the entire case. Under PTO 54 (Rec. Doc. 671), entered on July 21, 2017, Plaintiffs cannot

² http://www.laed.uscourts.gov/sites/default/files/local_rules/LAEDLocalCivilRules_4.pdf

³ The request should include the proposed motion, order and amending pleading, as well as documentation supporting product identification (if available).

“notice” a voluntary dismissal of all Defendants without prejudice. They must either move to dismiss, get stipulation to dismiss, or dismiss with prejudice. In any case, several procedural requirements must also be met and counsel should review the requirements of PTO 54. All voluntary dismissals without prejudice that would result in the dismissal of an entire action against all named Defendants require leave of Court by (i) motion or (ii) with stipulation of all served Defendants. With either a motion or stipulation, a Plaintiff must serve a completed Plaintiff Fact Sheet (“PFS”) and accompanying disclosures. In addition, with a motion, the Plaintiff must provide 14 days prior written notice to PLC and DLC and include a certification indicating either: (1) Defendants’ consent or no intended opposition to the motion, or (2) that the motion is opposed and the grounds for such opposition.

7. PLAINTIFF AND DEFENDANT FACT SHEETS

Counsel should note the rules of the PFS in several Pretrial Orders:

- a. Amended PTO 22 (Rec. Doc. 325) sets forth service of PFSs and Defendant Fact Sheets (“DFS”) and deadlines for service and deficiencies;
- b. PTO 23 (Rec. Doc. 280) amends Exhibit A which are the authorizations to PFS (Rec. Doc. 280);
- c. PTO 24 (Rec. Doc. 279) provides additional details on the service of fact sheets and authorizations through MDL Centrality and the PLC Distribution of Orders and Notices per PTO 1; and
- d. PTO 55 (Rec. Doc. 688) updated the form of the PFS. See Exhibit A to PTO 18 (Rec. Doc. 236-1).

Amended PTO 22 (Rec. Doc. 325) provides the timeframe for service of completed PFS and DFS forms; however, the Court has determined that the term “date of this order” in the Orders refers to the date of the initial PTO 22 (i.e., March 10, 2017).

As December 12, 2017, Plaintiffs have served 2,063 PFSs, and 662 PFSs are in progress. Based on the PFSs received as of December 12, 2017, 2017, they divide among

Defendants as follows: 1,076 sanofi, 143 Hospira, 57 Sandoz, 47 Accord, 405 Unknown, 118 Blank, 214 Other/Miscellaneous. The parties continue to confer on the status of photographic evidence submitted with fact sheets with PLC advising all Plaintiffs' counsel of the Court's statements on this issue, and enclosing copies of the transcript where the Court expressed its expectation, the descriptions of Plaintiffs' injuries in the Short Form complaints, the Deficiency Notices issued, and the status of product identification in multi-defendant cases.

Under Amended PTO 22 ¶ 5, sanofi identifies the approximately 89 cases attached hereto as Appendix C.7 as matters where no PFS, authorizations, or responsive documents have been submitted in violation of the Order. Sanofi accordingly requests that the Court issue a show cause order with notice pursuant to Amended PTO 22. *Id.*

Subject to the same provisions, Sanofi identifies the approximately 228 cases attached hereto as Appendix D.7 where Defendants issued deficiency notices on Plaintiffs' PFSs and Plaintiffs have failed to respond in any manner for thirty (30) days or more. Sanofi accordingly requests that the Court issue a show cause order with notice pursuant to Amended PTO 22. *Id.*

Subject to the same provisions, Sanofi also identifies the approximately 248 cases attached hereto as Appendix E.7 where Plaintiffs have failed to cure deficiencies related to the three categories of information needed to make the PFSs "substantially complete" as defined in Amended PTO 22. Sanofi accordingly requests that the Court issue a show cause order with notice pursuant to Amended PTO 22.

Under PTO 22 ¶ 5, the 505(b)(2) Defendants identify the approximately 9 cases attached hereto as Appendix F.7 as matters where no PFS, authorizations, or responsive documents have been submitted in violation of the Order. The 505(b)(2) Defendants accordingly request that the Court issue a show cause order with notice pursuant to Amended

PTO 22. *Id.*

Subject to the same provisions, the 505(b)(2) Defendants identify the approximately 4 cases attached hereto as Appendix G.7 where the 505(b)(2) Defendants issued deficiency notices on Plaintiffs' PFSs and Plaintiffs have failed to respond in any manner for thirty (30) days or more. The 505(b)(2) Defendants accordingly requests that the Court issue a show cause order with notice pursuant to Amended PTO 22. *Id.*

Subject to the same provisions, the 505(b)(2) Defendants also identify the approximately 4 cases attached hereto as Appendix H.7 where Plaintiffs have failed to cure deficiencies related to the three categories of information needed to make the PFSs "substantially complete" as defined in Amended PTO 22. The 505(b)(2) Defendants accordingly request that the Court issue a show cause order with notice pursuant to Amended PTO 22.

Subject to these provisions, both Sanofi and the 505 (b)(2) Defendants identify 122 cases attached hereto as Appendix I.7 where Plaintiffs have failed to cure deficiencies identified in Joint Report No. 6 of Liaison Counsel, Appendices C, D, E, F, G, H (Rec. Docs. 1064-3, 1064-4, 1064-5, 1064-6, 1064-7, and 1064-8). Under the authority of Amended PTO 22 and the Court's Order to Show Cause No. 2 (Rec. Doc. 1103), each Plaintiff listed on Appendix I.7 has been ordered to Show Cause by December 15, 2017 in writing, limited to two (2) double-spaced pages, on why Plaintiff's case should not be dismissed. *See* Order to Show Cause No. 2 (Rec. Doc. 1103). Defendants are not required to submit a response unless otherwise ordered by the Court. Any Plaintiff who has not complied with these requirements is subject to dismissal.

8. MDL CENTRALITY

Fillable versions of the Plaintiff Fact Sheet and Defense Fact Sheet are on the Court's

MDL 2740 website under the tab “Forms,” as well as on the BrownGreer website.

The parties are working on non-substantive changes to the PFS on MDL Centrality . Once the changes have been made, PLC will give notify all counsel who have signed and submitted a Counsel Contact Form. The new PFS will be put on the Court’s website as well as on MDL Centrality.

9. SERVICE ON DEFENDANTS

Counsel for sanofi and the Plaintiffs’ Steering Committee (“PSC”) have agreed to a streamlined service procedure set forth in PTO 9 (Rec. Doc. 160) for service of complaints on the domestic sanofi entity. Sanofi acknowledges that service of a complaint naming Winthrop US may be made on Sanofi-aventis U.S. LLC.

Counsel for several Defendants have also agreed to streamlined service procedures: for Accord Healthcare, Inc., a streamlined service procedure is in PTO 29 (Rec. Doc. 303); for Sandoz Inc. in PTO 30 (Rec. Doc. 304); for Actavis Pharma, Inc. in PTO 32A (Rec. Doc. 710); for McKesson Corporation in PTO 33 (Rec. Doc. 308); for Sun Pharma, Inc. in PTO 39A (Rec. Doc. 711); and for Hospira Worldwide, LLC in PTO 40A (Rec. Doc. 509) that amends and supersedes PTO 40 (Rec. Doc. 328).

10. DISMISSAL OF DEFENDANTS

Three entities, who were originally named as Defendants, have been dismissed in all cases pending in the MDL. One entity (Apotex, Inc.) submitted proof by affidavit that it did not manufacture Docetaxel. The other entities, Northstar RX, LLC and Eagle Pharmaceuticals, Inc., submitted proof that they did not manufacture Docetaxel until after the date of infusions alleged in the individual Complaints. The referenced documents are as follows: Northstar RX LLC (Rec. Docs. 320, 324, 333, 335), Eagle Pharmaceuticals, Inc. (Rec. Doc. 319, 332, 336),

and Apotex, Inc. (Rec. Docs. 219, 224, 225).

The Defendants have communicated with Plaintiffs and PLC seeking dismissal in cases where (i) a Plaintiff's PFS identified a different manufacturer of Taxotere/docetaxel, (ii) Plaintiffs' records reflect treatment only with Taxotere/docetaxel manufactured by a different Defendant, and/or (iii) Plaintiffs' records indicate treatment dates prior to the availability of the Defendant's product on the market. Plaintiffs and Defendants are meeting and conferring regarding these requests for dismissal. The PSC and all Defendants agree to make a concerted effort to ensure that only the proper Defendants are named. The PSC and all Defendants are meeting and conferring on a proposed PTO to on Product Identification to ensure that the proper Defendant manufacturers are named in a complaint. The parties are prepared to discuss this issue at the status conference.

On November 3, 2017 the parties filed Stipulation of Terms Related To Defendants, Sanofi and Aventis Pharma S.A. (Rec. Doc. 1072). At the Court's request, the parties have drafted an *en globo* Motion to Dismiss the French Defendants from all cases in the MDL. (The exemplar Short Form Complaint has also been amended to remove these entities.) Counsel do not have to move to dismiss the French Defendants in any individual case.

11. PRESERVATION ORDER

Counsel are reminded to familiarize themselves with the terms of PTO 1 (Rec. Doc. 4, ¶12) regarding preservation of evidence. The parties will meet and confer if it becomes appropriate to modify, amend or supplement PTO No. 1 regarding Preservation Order. (Rec. Doc. No. 4). Pursuant to negotiations with the U.S. sanofi Defendants, PLC circulated an additional letter on preservation to all Plaintiffs' counsel known at the time.

12. PROTECTIVE ORDER

Magistrate Judge North entered the Protective Order on July 5, 2017, as PTO 50 (Rec. Docs. 612-1, 613).

13. ELECTRONICALLY STORED INFORMATION (ESI) DISCOVERY

Magistrate Judge North entered the Electronically Stored Information Protocol on July 5, 2017 as PTO 49 (Rec. Docs. 611-1, 613). The Sanofi Defendants filed a Motion to Compel Production of Electronically Stored Information. (Rec. Doc. 918). The Plaintiffs opposed the motion. (Rec. Doc. 977). The Motion was withdrawn by the Sanofi Defendants. At the October 27, 2017 Steering Committee Meeting and Status Conference, the Court requested that the parties make letter submissions concerning issues related to Plaintiffs' production of photographs and ESI. On December 15, 2017 the Court issued Pretrial Order No. 71 (Rec. Doc 1306) regarding Plaintiffs' Responsibilities Relevant to ESI. This Order requires specified searches and certification of compliance by both Plaintiff and Plaintiffs' Counsel. If a PFS or other request for production by Defendants as of the date of the Order has been previously submitted, both counsel and the Plaintiff have 45 days from the date of this Order to provide the written statement described in paragraph 6 of the Order. Forty-five (45) days from the date of the Order is Monday, January 29, 2018.

14. DISCOVERY OF DEFENDANTS

Plaintiffs have served merits discovery on Sanofi, and the Sanofi Defendants have begun the process of producing responsive documents. The parties have met and conferred multiple times about this discovery served by the Plaintiffs. The parties are generally addressing discovery disputes with Magistrate Judge North. The future dates scheduled by Magistrate Judge North are December 27, 2017 at 10:00 CT (telephonic) and January 9, 2018 at 10:00 CT (in person status conference).

Plaintiffs recently served merits discovery on Accord Healthcare, Inc., the

Hospira/Pfizer Defendants, and Sandoz Inc. Plaintiffs and these Defendants intend to meet and confer regarding this discovery and generally will address any disputes before Magistrate Judge North.

15. MOTION PRACTICE

- a. On May 26, 2017, sanofi filed a Motion to Dismiss Claims Barred by the Applicable Statutes of Limitations. (Rec. Doc. 494). The Court denied the Motion without Prejudice on October 26, 2017. (Rec. Doc. No. 1034).
- b. On October 3, 2017, Defendants filed a Motion for the entry of a case substitution protocol (Rec. Doc. 888). The Court denied the Motion without prejudice. (Rec. Doc. 1136)
- c. On October 5, 2017, sanofi filed a Motion to permit written discovery on the Trial Pool Plaintiffs. (Rec. Doc. 905). The Court granted the motion. (Rec. Doc. 1138)
- d. On October 10, 2017, Sanofi-Aventis U.S. LLC and Sanofi US Services, Inc.'s filed a Motion for Entry of a protocol Regarding *Ex Parte* Contact With Physicians. (Rec. Doc. 917). The Court entered Pretrial Order 70 Regarding Contact with Physicians, denying it in part and granting it in part. (Rec. Doc. 1137).

16. CLASS CERTIFICATION BRIEFING

Class Certification of a putative Louisiana class of Plaintiffs was denied by the Court on July 17, 2017. (Rec. Doc. 647).

17. SETTLEMENT COMMITTEES

Pursuant to PTO 6 (Rec. Doc. 133), the Court appointed representatives to a Plaintiff's Settlement Committee, and to a sanofi Settlement Committee, and in PTO 44 (Rec. Doc. 371) a

separate Settlement Committee for the non-sanofi Defendants, referred to as the 505(b)(2) Defendants. Settlement Committees are tasked with maintaining a continuing, collaborative discussion of the elements and characteristics of a framework for potential resolution of cases. The sanofi Settlement Committee and the Plaintiffs' Settlement Committee recently met in person to discuss relevant issues. The 505(b)(2) Defendants' Settlement Committee and the Plaintiff's Settlement Committee continue to have dialogue. The Chairs of each Settlement Committee met with the Court at the conclusion of the Status Conference.

Counsel are reminded of the reporting requirements to identify unfiled cases of PTO 60 (Order Regarding the Collection of Data of Potential Claimants by the Plaintiffs' Settlement Committee) (Rec. Doc. 819). The next date to update the form required by PTO 60 is December 31, 2017.

18. SPECIAL MASTER FOR PLAINTIFFS' TIME AND EXPENSES

In PTO 20 (Rec. Doc. 265) the Court appointed Kenneth W. DeJean as Special Master for the Plaintiffs to review the time and expenses submitted as common benefit during the course of the MDL. The Court has met with and communicated with the Special Master to discuss the time and expenses submitted. The Special Master is working in the time and expense reporting system, having begun his first review of the time and expenses submitted. The Court and the Special Master will have a telephonic conference next week.

19. NEXT STATUS CONFERENCE

The Court has announced that the next general status conference will be held on March 7, 2018, at 10:00 a.m. in Judge Engelhardt's courtroom, with the meeting of Liaison Counsel at 8:30 a.m. in Chambers, and the meeting of the PSC and the defendants' Lead Counsel at 9:00 a.m. The Court has set up a telephone conference line for the status conference that begins at

10:00 a.m.

To join the status conference by telephone at 10:00 a.m., please use the call-in information on the Court's website under the tab "Upcoming Events."

Dated: January 26, 2018

Respectfully submitted:

/s/Dawn M. Barrios

Dawn M. Barrios (#2821)

**Barrios, Kingsdorf & Casteix,
LLP**

701 Poydras Street, Suite 3650

New Orleans, LA 70139

Telephone: 504-524-3300

Facsimile: 504-524-3313

E-Mail: barrios@bkc-law.com

*Plaintiffs' Co-Liaison
Counsel*

/s/ Douglas J. Moore

Douglas J. Moore (Bar No. 27706)

**IRWIN FRITCHIE URQUHART
& MOORE LLC**

400 Poydras Street, Suite 2700

New Orleans, LA 70130

Telephone: 504-310-2100

Facsimile: 504-310-2120

E-Mail: dmoore@irwinllc.com

*Defendants' Liaison
Counsel*

/s/M. Palmer Lambert

M. Palmer Lambert (#33228)

**Gainsburgh Benjamin David Meunier
& Warshauer, LLC**

2800 Energy Centre, 1100 Poydras Street

New Orleans, LA 70163-2800

Telephone: 504-522-2304

Facsimile: 504-528-9973

E-Mail: plambert@gainsben.com

Plaintiffs' Co-Liaison Counsel

/s/ John F. Olinde

John F. Olinde (Bar No. 1515)

CHAFFE MCCALL, L.L.P.

1100 Poydras Street

New Orleans, LA 70163

Telephone: 504-585-7000

Facsimile: 504-585-7075

E-Mail: olinde@chaffe.com

Defendants' Liaison Counsel

CERTIFICATE OF SERVICE

I hereby certify that on January 26, 2018, I electronically filed the foregoing with the Clerk of Court by using the CM/ECF system which will send a notice of electronic filing to all counsel of record who are CM/ECF participants.

/s/M. Palmer Lambert
M. Palmer Lambert

APPENDIX A.7

PRETRIAL ORDERS

Pretrial Order No. 1 (Rec. Doc. 4) entered October 13, 2016 – Setting initial conference.

Pretrial Order No. 2 (Rec. Doc. 104) entered November 17, 2016 – Appointing Plaintiffs’ Liaison Counsel, Plaintiffs’ Steering Committee, and Defendants’ Liaison Counsel.

Pretrial Order No. 3 (Rec. Doc. 115) entered November 30, 2016 – Filing Requests for Summons and Summons Returns.

Pretrial Order No. 4 (Rec. Doc. 122) entered December 9, 2016 – Procedures for Direct Filing into the MDL [**superseded by PTO 5**].

Pretrial Order No. 5 (Rec. Doc. 131) entered December 13, 2016 – Amended Procedures for Direct Filing into the MDL.

Pretrial Order No. 6 (Rec. Doc. 133) entered December 13, 2016 – Appointing Settlement Committees.

Pretrial Order No. 7 (Rec. Doc. 155) entered December 28, 2016 – Approving and attaching Counsel Contact Information Form.

Pretrial Order No. 8 (Rec. Doc. 156) entered December 30, 2016 – Federal-State Coordination and Cooperation.

Pretrial Order No. 9 (Rec. Doc. 160) entered January 3, 2017 – Streamlined Service on sanofi-Aventis U.S. LLC.

Pretrial Order No. 10 (Rec. Doc. 169) entered January 11, 2017 – JPML Clarification on Scope of MDL.

Pretrial Order No. 11 (Rec. Doc. 170) entered January 11, 2017 – Extending Deadline to Submit Proposed PFS and DFS.

Pretrial Order No. 12 (Rec. Doc. 191) entered January 20, 2017 – Directing that Service of Process shall be made on all known, non-sanofi Defendants by February 15, 2017; Directing Liaison Counsel to Provide Proposed Deadlines for Close of Pleadings.

Pretrial Order No. 13 (Rec. Doc. 209) entered January 31, 2017 – Appointing Brian S. Rudick to the Settlement Committee.

Pretrial Order No. 14 (Rec. Doc. 216) entered February 3, 2017 – Order from January 27, 2017 Status Conference.

Pretrial Order No. 15 (Rec. Doc. 230) entered February 10, 2017 – Order setting deadlines for Master and Short Form Complaint, Motions to Dismiss and Master Answer.

Pretrial Order No. 16 (Rec. Doc. 234) entered February 13, 2017 – Intention to Enter Common Benefit, Time and Expense Rules, Appointment of CPA, Holdback, Assessments, and Related Issues.

Pretrial Order No. 17 (Rec. Doc. 235) entered February 13, 2017 – Intention to Appoint Kenneth W. DeJean as Special Master.

Pretrial Order No. 18 (Rec. Doc. 236) entered February 14, 2017 – Ordering the use of the attached Plaintiff Fact Sheets and Defense Fact Sheets. See also R.Doc. 236-1.

Pretrial Order No. 19 (Rec. Doc. 262) entered February 23, 2017 – Adopting the proposed Common Benefit Order submitted by Liaison Counsel and the Plaintiffs' Steering Committee.

Pretrial Order No. 20 (Rec. Doc. 265) entered February 24, 2017 – Appointing Kenneth W. DeJean as Special Master.

Pretrial Order No. 21 (Rec. Doc. 276) entered March 7, 2017 – Setting Deadlines following March 6, 2017 meeting with liaison counsel.

Pretrial Order No. 22 (Rec. Doc. 279) entered March 10, 2017 – Implementation of Deadlines for Service of Fact Sheets and Deficiencies.

Pretrial Order No. 23 (Rec. Doc. 280) entered March 10, 2017 – Amending Exhibit A to Pretrial Order No. 18 (R. Doc. 236-1) to include the authorizations approved by the Court.

Pretrial Order No. 24 (R. Doc. 286) entered March 16, 2017 – Guidelines for service of Fact Sheets through MDL Centrality and Plaintiff Liaison Counsel Distribution of Orders and Notices per Pretrial Order No. 1.

Pretrial Order No. 25 (R. Doc. 287) entered March 16, 2017 – Appointing John F. Olinde to serve as Liaison Counsel for the non-Sanofi defendants.

Pretrial Order No. 26 (Rec. Doc. 289) entered March 17, 2017 – Designating Defense Counsel to Attend Plaintiffs' Steering Committee Meetings

Pretrial Order No. 26A (Rec. Doc. 598) entered June 28, 2017 – Modification to Designation of Defense Counsel to Attend Plaintiffs' Steering Committee Meetings

Pretrial Order No. 27 (Rec. Doc. 298) entered March 24, 2017 – Order from March 17, 2017 Status Conference

Pretrial Order No. 28 (Rec. Doc. 302) entered March 27, 2017 – Setting a Meeting with Liaison Counsel

Pretrial Order No. 29 (Rec. Doc. 303) entered March 27, 2017 – Streamlined Service on Accord Healthcare, Inc.

Pretrial Order No. 30 (Rec. Doc. 304) entered March 27, 2017 – Streamlined Service on Sandoz, Inc.

Pretrial Order No. 31 (Rec. Doc. 305) entered March 27, 2017 – Amended Task Codes for Common Benefit Order

Pretrial Order No. 32 (Rec. Doc. 307) entered March 31, 2017 – Streamlined Service on Actavis Pharma, Inc.

Pretrial Order No. 33 (Rec. Doc. 308) entered March 31, 2017 – Streamlined Service on McKesson Corporation

Pretrial Order No. 34 (Rec. Doc. 309) entered March 31, 2017 – Extending the Deadline to Submit Proposed Orders for Streamlined Service as to Eagle Pharmaceuticals, Inc. and NorthStar Rx LLC

Pretrial Order No. 35 (Rec. Doc. 310) entered March 31, 2017 – Scheduling Meetings between the Court and the Settlement Committees

Pretrial Order No. 36 (Rec. Doc. 317) entered April 6, 2017 – Withdrawal of Deadline to Submit Proposed Orders Regarding Streamlined Service as to Eagle Pharmaceuticals, Inc. and NorthStar Rx LLC

Pretrial Orders No. 37 and 41 (Rec. Docs. 318 and 331) entered April 6, 2017 and April 17, 2017 – Exemplar Short Form Complaint and superseding and amending Exemplar Short Form Complaint.

Pretrial Order No. 38 (Rec. Doc. 326) entered on April 12, 2017- Amending PFS and DFS

Pretrial Order No. 39 (Rec. Doc. 327) entered on April 11, 2017- Streamlined Service on Sun Pharma Global, Inc.

Pretrial Order No. 40 (Rec. Doc. 328) entered on April 12, 2017- Streamlined Service on Hospira Worldwide, LLC and Pfizer Inc.

Pretrial Order No. 40A (Rec. Doc. 509) entered June 1, 2017 – Amending Pretrial Order No. 40 regarding Streamlined Service on Hospira Worldwide, LLC and Pfizer, Inc.

Pretrial Order No. 42 (Rec. Doc. 348) entered on April 26, 2017- Responsive Pleadings to Short Form Complaints Reserved

Pretrial Order No. 43 (Rec. Doc. 349) entered April 27, 2017- Regarding July 7, 2017 Status Conference, 505(b)(2) Defendant Settlement Committee, “Science Day,” Remand Motions and Discovery Schedule

Pretrial Order No. 44 (Rec. Doc. 371) entered May 11, 2017 – Order Appointing 505(b)(2) Defendants’ Settlement Committee

Pretrial Order No. 45 (Rec. Doc. 458) entered May 12, 2017 – Setting the Briefing Schedule for the Omnibus Motions to Remand

Pretrial Order No. 46 (Rec. Doc. 462) entered May 16, 2017 – Order from May 12, 2017 Status Conference

Pretrial Order No. 47 (Rec. Doc. 534) entered June 13, 2017 – Granting Requests for Oral Argument on Omnibus Motions to Remand

Pretrial Order No. 48 (Rec. Doc. 566) entered June 28, 2017 – Resetting Oral Argument on Omnibus Motions to Remand

Pretrial Order No. 49 (Rec. Docs. 611, 613) entered July 5, 2017 – Electronically Stored Information Protocol

Pretrial Order No. 50 (Rec. Docs. 612, 613) entered July 5, 2017 – Protective Order

Pretrial Order No. 51 (Rec. Doc. 660) entered July 18, 2017- Order from July 7, 2017 Status Conference

Pretrial Order No. 52 (Rec. Doc. 661) entered July 18, 2017- Amended Deadlines Regarding Personal Jurisdiction and Potential Discovery Protocols

Pretrial Order No. 53 (Rec. Doc. 664) entered July 20, 2017- Amendments to Plaintiffs' Master Long Form Complaint, Exemplar Short Form Complaint and Plaintiffs' Fact Sheet

Pretrial Order No. 54 (Rec. Doc. 671) entered July 21, 2017- Docket Control Order- Voluntary Dismissals

Pretrial Order No. 55 (Rec. Doc. 688) entered July 25, 2017- Order Regarding the Filing of the Amended Master Long Form Complaint and Substitution of the Amended Exemplar Short Form Complaint and Amended Plaintiff Fact Sheet

Pretrial Order No. 56 (Rec. Doc. 712) entered August 2, 2017- Issuance of Summons with Corrected Defendants' Names

Pretrial Order No. 57 (Rec. Doc. 718) entered August 3, 2017- Setting a Meeting with Liaison Counsel

Pretrial Order No. 58 (Rec. Doc. 744) entered August 18, 2017- Granting Request for Oral Argument on Defendants' Motion to Dismiss Plaintiffs' Master Long Form Complaint (Rec. Doc. 489)

Pretrial Order No. 59 (Rec. Doc. 816) entered September 7, 2017- Resetting the Submission Date on Defendants' Motion to Dismiss Claims Barred by the Applicable Statutes of Limitations (Rec. Doc. No. 494)

Pretrial Order No. 60 (Rec. Doc. 819) entered September 7, 2017- Ordering Collection of Data of Potential Claimants by the Plaintiffs' Settlement Committee.

Pretrial Order No. 60A (Rec. Doc. 870) entered September 15, 2017- Amending and Superseding Order Regarding Collection of Data of Potential Claimants by the Plaintiffs' Settlement Committee.

Pretrial Order No. 61 (Rec. Doc. 877) entered September 27, 2017- Ordering the Dismissal of Count Two and Count Eight of the Master Long Form Complaint (Rec. Doc. 489).

Pretrial Order No. 62 (Rec. Doc. 878) entered September 27, 2017- Ordering that the deadline for each Defendant to file their Master Answer be set for Monday, October 16, 2017.

Pretrial Order No. 63 (Rec. Doc. 879) entered September 27, 2017- Ordering that the meeting of liaison counsel with the Court take place on Friday, October 6, 2017, at 9:30 a.m.

Pretrial Order No. 64 (Rec. Doc. 941) entered October 13, 2017- Ordering Clarifying the Court's Ruling (Rec. Doc. 784) on California Plaintiffs' Motion to Remand.

Pretrial Order No. 65 (Rec. Doc. 959) entered October 16, 2017- Ordering Severance of Multi- Plaintiff Cases.

Pretrial Order No. 66 (Rec. Doc. 1018) entered October 25, 2017- Order Clarifying this Court's Ruling on Delaware Motion to Remand (Rec. Doc. 784).

Pretrial Order No. 67 (Rec. Doc. 1032) entered October 27, 2017 – Order setting the next liaison counsel meeting for November 17, 2017, at 9:30 AM, and setting the next General Status Conference for December 15, 2017, at 10:00 AM.

Pretrial Order No. 68 (Rec. Doc. 1085) entered November 9, 2017- Setting Deadlines following October 27, 2017 meeting with Steering Committees.

Pretrial Order No. 69 (Rec. Doc. 1095) entered November 14, 2017- Setting Deadline for submission of applications for Court appointed positions with MDL 2740.

Pretrial Order No. 70 (Rec. Doc. 1137) entered November 21, 2017- Order regarding contact with physicians.

Pretrial Order No. 71 (Rec. Doc. 1306) entered December 15, 2017- Order governing

Plaintiffs' responsibilities relevant to ESI.

Pretrial Order No. 72 (Rec. Doc. 1462) entered January 4, 2018 regarding dismissal of the French Sanofi Defendants per Stipulation.

Pretrial Order No. 73 (Rec. Doc. 1463) entered January 4, 2018 regarding Revised Exemplar Short Form Complaint.

Pretrial Order No. 74 (Rec. Doc. 1470) entered January 4, 2018 regarding Procedures for Withdrawal of Counsel.

Pretrial Order No. 75 (Rec. Doc. 1507) entered January 12, 2018 regarding Reappointment of Counsel in MDL 2740.

APPENDIX B.7

Case Management Orders

Case Management Order No. 1 (Rec. Doc. 465) entered May 18, 2017- Personal Jurisdiction Discovery

Case Management Order No. 2 (Rec. Doc. 474) entered May 23, 2017- Discovery on French Sanofi Entities

Case Management Order No. 3 (Rec. Doc. 669) entered July 21, 2017- Trial Scheduling Order

Case Management Order No. 4 (Rec. Doc. 670) entered July 21, 2017- Protocol for Initial Phase of Case-Specific Discovery for Cases Identified in Case Management Order No. 3

Case Management Order No. 5 (Rec. Doc. 762) entered August 23, 2017- General Discovery Protocol- Sanofi Defendants

Case Management Order No. 6 (Rec. Doc. 780) entered August 29, 2017- Setting Four Bellwether Trial Dates in 2019

Case Management Order No. 7 (Rec. Doc. 915) entered October 10, 2017- General Discovery Protocol – 505(b)(2) Defendants

Case Management Order No. 8 (Rec. Doc. 935) entered October 11, 2017- Trial Scheduling Order for MDL Trial No. 2

Case Management Order No. 8A (Rec. Doc. 1099) entered on November 14, 2017- That Amends and Supersedes CMO No. 8 (Trial Scheduling Order- MDL Trial No. 2)

Case Management Order No. 9 (Rec. Doc. 1110) entered on November 15, 2017- Deposition Protocol

Case Management Order No. 10 (Rec Doc 1168) entered on December 8, 2017 - Protocol for Initial Phase of Case-Specific Discovery re Cases in CMO 8A

Case Management Order No. 11 (Rec Doc 1430) entered on December 27, 2017 - Extension of Certain Deadlines in CMO 3

Case Management Order No. 12 (Rec. Doc. 1506) entered January 12, 2018 setting forth a Process for Obtaining Product Identification for Multi-Defendant Cases.

APPENDIX C.7

Missing PFS (Sanofi Defendants)

Matter Name	MDL Docket No.
Alexander, Sheila v. Sanofi SA, et al.	2:17-cv-08760
Alvillar, Diane L. v. Sanofi SA, et al.	2:17-cv-09635
Blackwell, Judith M. v. Sanofi SA, et al.	2:17-cv-09398
Boynton, Sandra v. Sanofi SA, et al.	2:17-cv-09241
Burton, Tammy v. Sanofi SA, et al.	2:17-cv-08634
Cherry, Pauline C. v. Sanofi SA, et al.	2:17-cv-08370
Cooper, Nancy v. Sanofi SA, et al.	2:17-cv-08658
Curry, Mattie B. v. Sanofi SA, et al.	2:17-cv-09266
Curtis, Nellie v. Sanofi SA, et al.	2:17-cv-08626
Davis, Diane (VT) v. Sanofi SA, et al.	2:17-cv-07812
Douglas, Janie C. and Leel v. Sanofi SA, et al.	2:17-cv-09638
Etheridge, Carisa v. Sanofi SA, et al.	2:17-cv-09431
Frankenberg, Kim v. Sanofi SA, et al.	2:17-cv-08564
Frazier, Sylvonia v. Sanofi SA, et al.	2:17-cv-09083
Freeman, Rachael M. v. Sanofi SA, et al.	2:17-cv-08804
Gardner, Mary v. Sanofi SA, et al.	2:17-cv-03865
Gibson, Debbie v. Sanofi SA, et al.	2:17-cv-09652
Gibson, Peggy v. Sanofi SA, et al.	2:17-cv-09576
Gladden, Juliann M. v. Sanofi SA, et al.	2:17-cv-08801
Godfrey, Patricia Ann v. Sanofi SA, et al.	2:17-cv-07809
Goforth, Carol v. Sanofi SA, et al.	2:17-cv-08321
Gogan, Linda M. and Michael v. Sanofi SA, et al.	2:17-cv-09581
Gordon, Donna v. Sanofi SA, et al.	2:17-cv-08653
Graham, Hattie M. and Tommy v. Sanofi SA, et al.	2:17-cv-09592
Grant, Flora v. Sanofi SA, et al.	2:16-cv-17940
Grays, Faith v. Sanofi SA, et al.	2:17-cv-08568
Griffin, Theresa E. v. Sanofi SA, et al.	2:17-cv-09050
Hall, Linda Jean v. Sanofi SA, et al.	2:17-cv-08864
Harris, Jacqueline v. Sanofi SA, et al.	2:17-cv-08829
Hegidio, Katharine M. v. Sanofi SA, et al.	2:17-cv-09579
Henderson-Moore, Donna v. Sanofi SA, et al.	2:17-cv-09575
Henly, Debra L. v. Sanofi SA, et al.	2:17-cv-09604
Herman, Lynne v. Sanofi SA, et al.	2:17-cv-08320

Matter Name	MDL Docket No.
Hollis, Patricia P. v. Sanofi SA, et al.	2:17-cv-02354
Holt, Melita v. Sanofi SA, et al.	2:17-cv-08561
Horne, Pazetta v. Sanofi SA, et al.	2:17-cv-08654
Howell, Wyskanna v. Sanofi SA, et al.	2:17-cv-08501
Jiles, Sharon v. Sanofi SA, et al.	2:17-cv-08999
Johnson, Hilda v. Sanofi SA, et al.	2:17-cv-08637
Johnson, Petrina S. v. Sanofi SA, et al.	2:17-cv-08811
Johnson, Tena v. Sanofi SA, et al.	2:17-cv-08680
Jordan, Sheila v. Sanofi SA, et al.	2:17-cv-08824
Klotz, Kelly v. Sanofi SA, et al.	2:17-cv-08827
Lee, Wanda v. Sanofi SA, et al.	2:17-cv-09658
Lewis, Joyce Etta v. Sanofi SA, et al.	2:17-cv-08993
Lopez, Ruth v. Sanofi SA, et al.	2:17-cv-08993
Lozano, Maria v. Sanofi SA, et al.	2:17-cv-08655
Luckett, Jennifer v. Sanofi SA, et al.	2:17-cv-04752
Luckey, Donna v. Sanofi SA, et al.	2:17-cv-08826
Madden, Debbie v. Sanofi SA, et al.	2:17-cv-09473
Madison, Perrine v. Sanofi SA, et al.	2:17-cv-09660
Marshall, Nancy v. Sanofi SA, et al.	2:17-cv-09476
Martin, Flora Jean v. Sanofi SA, et al.	2:17-cv-11247
Matthews, Charlsie v. Sanofi SA, et al.	2:17-cv-10024
McCuin-Hutchins, Sharon v. Sanofi SA, et al.	2:17-cv-09438
Milligan, Murrall v. Sanofi SA, et al.	2:17-cv-08759
Mills, Linda v. Sanofi SA, et al.	2:17-cv-09348
Mitchell, Angela v. Sanofi SA, et al.	2:17-cv-06409
Moore, Linda M. v. Sanofi SA, et al.	2:17-cv-09396
Pitta, Rhonda v. Sanofi SA, et al.	2:17-cv-08761
Pointer, Lisa v. Sanofi SA, et al.	2:17-cv-08758
Pressley, Sandra v. Sanofi SA, et al.	2:17-cv-08661
Radwan, Mona v. Sanofi SA, et al.	2:17-cv-08638
Richardson, Regina A. and Ronald v. Sanofi SA, et al.	2:17-cv-09400
Sabatini, Marie Claire v. Sanofi SA, et al.	2:17-cv-08319
Sanchez, Heather v. Sanofi SA, et al.	2:17-cv-08641
Sanchez, Kathryn v. Sanofi SA, et al.	2:17-cv-08644
Sharpe, Joyce v. Sanofi SA, et al.	2:17-cv-08628
Shelton, Renee v. Sanofi SA, et al.	2:17-cv-09367
Shields, Betty v. Sanofi SA, et al.	2:17-cv-08629
Simms, Joan v. Sanofi SA, et al.	2:17-cv-09574

Matter Name	MDL Docket No.
Smith, Mary J. v. Sanofi SA, et al.	2:17-cv-08648
Smith, Nancy (CO) v. Sanofi SA, et al.	2:17-cv-08828
Stark, Carrie v. Sanofi SA, et al.	2:17-cv-08633
Straub, Tami v. Sanofi SA, et al.	2:17-cv-08492
Taylor, Sharon M. V. Sanofi SA, et al.	2:17-cv-09665
Thomas, Lee Ann v. Sanofi SA, et al.	2:17-cv-09345
Thomas, Linda v. Sanofi SA, et al.	2:17-cv-08642
Thomas, Saundra v. Sanofi SA, et al.	2:17-cv-09069
Trevino, Aster v. Sanofi SA, et al.	2:17-cv-09026
Ullery, Jackie v. Sanofi SA, et al.	2:17-cv-09511
Unger, Jacqueline v. Sanofi SA, et al.	2:17-cv-08635
Vatter, Nancy v. Sanofi SA, et al.	2:17-cv-08657
Walker, Daisy v. Sanofi SA, et al.	2:17-cv-09625
Ware, Beverly v. Sanofi SA, et al.	2:17-cv-08646
Westbrook, Denise v. Sanofi SA, et al.	2:17-cv-09499
Whitehead, Darlene v. Sanofi SA, et al.	2:17-cv-08621
Williams, Geneva v. Sanofi SA, et al.	2:17-cv-08966
Zapien, Kimberlie v. Sanofi SA, et al.	2:17-cv-08636

APPENDIX D.7

No Deficiency Response (Sanofi Defendants)

Matter Name	MDL Docket No.
Abel et al v. Sanofi S.A. et al	2:17-cv-01354
Allen v. Sanofi S.A. et al	2:16-cv-17065
Anderson v. Sanofi S.A. et al	2:16-cv-15493
Anderson v. Sanofi S.A. et al	2:16-cv-17139
Anderson v. Sanofi S.A. et al	2:16-cv-17498
Ankner vs. Sanofi S.A. et al	2:16-cv-17312
Ariks vs. Sanofi S.A. LLC et al	2:16-cv-17328
Aronowitz v. Sanofi S.A. et al	2:17-cv-05640
Baker v. Sanofi S.A. et al	2:16-cv-17154
Bass v. Sanofi S.A. et al	2:17-cv-02254
Batie et al v. Sanofi S.A. et al	2:16-cv-16233
Bell v. Sanofi S.A. et al	2:16-cv-17108
Bemiss v. Sanofi S.A. et al	2:16-cv-06425
Bentley v. Aventis Pharma S.A. et al	2:16-cv-17501
Bias v. Sanofi S.A. et al	2:16-cv-17171
Bodker v. Sanofi S.A. et al	2:17-cv-03426
Borowski v. Sanofi S.A. et al	2:17-cv-06493
Boyland v. Sanofi S.A. et al	2:17-cv-00793
Breslauer v. Sanofi S.A. et al	2:17-cv-01199
Brooks v. Sanofi S.A. et al	2:16-cv-17054
Broussard v. Sanofi S.A. et al	2:16-cv-15665
Brown v. Sanofi S.A. et al	2:16-cv-15512
Brown v. Sanofi S.A. et al	2:16-cv-17160
Brown v. Sanofi S.A. et al	2:17-cv-00800
Burks v. Sanofi S.A. et al	2:17-cv-01738
Burnstein v. Sanofi S.A. et al	2:16-cv-17172
Butler v. Sanofi S.A. et al	2:17-cv-02135
Butlers v. Sanofi S A et al	2:16-cv-17946
Carbino et al v. Sanofi-Aventis U.S. LLC et al	2:17-cv-00539
Carson v. Sanofi S.A. et al	2:16-cv-15322
Carter v. Sanofi S.A. et al	2:17-cv-00047
Carver v. Sanofi S.A. et al	2:16-cv-17192
Caye v. Sanofi S.A. et al	2:17-cv-04726
Champagne v. Sanofi S.A. et al	2:16-cv-17174
Chappell v. Sanofi S.A. et al	2:16-cv-17163

Matter Name	MDL Docket No.
Chase v. Sanofi S.A. et al	2:16-cv-15317
Cherem v. Sanofi S.A. et al	2:17-cv-00119
Chorak v. Sanofi S.A. et al	2:16-cv-17165
Clendenon v. Sanofi S.A. et al	2:16-cv-17157
Clinton v. Sanofi S.A. et al	2:16-cv-15814
Collins v. Sanofi S.A. et al	2:16-cv-15281
Couvillier v. Sanofi S.A. et al	2:16-cv-16938
Craddock v. Sanofi S.A. et al	2:16-cv-15572
Crawford v. Sanofi S.A. et al	2:16-cv-17151
Culpepper v. Sanofi S.A. et al	2:16-cv-17914
Cyprian v. Sanofi S.A. et al	2:16-cv-15661
Daley v. Sanofi S.A. et al	2:17-cv-04825
dams v. Sanofi S.A. et al	2:16-cv-16299
Daniels v. Sanofi S.A. et al	2:17-cv-05275
Daughtry v. Sanofi S.A. et al	2:16-cv-17053
Davis v. Sanofi S.A. et al	2:16-cv-17985
Davis v. Sanofi S.A. et al	2:17-cv-02309
Davis v. Sanofi S.A. et al	2:17-cv-05900
Dean v. Sanofi S.A. et al	2:16-cv-17201
Deggs v. Sanofi S.A. et al	2:17-cv-00588
Derrick v. Sanofi S.A. et al	2:17-cv-02454
Detrixhe v. Sanofi S.A. et al	2:16-cv-15313
Dimbo v. Sanofi S.A. et al	2:16-cv-17057
Doering et al v. Sanofi S.A. et al	2:17-cv-06245
Doughty v. Sanofi S.A. et al	2:17-cv-05268
Downs v. Sanofi S.A. et al	2:17-cv-01106
Drew v. Sanofi S.A. et al	2:17-cv-06345
Dukes v. Sanofi S.A. et al	2:16-cv-17048
Edwards-Woodard et al v. Sanofi-Aventis U.S. LLC et al	2:16-cv-16799
Elkins v. Sanofi S.A. et al	2:16-cv-16657
Erkins v. Sanofi S.A. et al	2:16-cv-17131
Folks v. Sanofi S.A. et al	2:16-cv-17579
Fuller v. Sanofi S.A. et al	2:16-cv-17231
Gabriel v. Sanofi S.A. et al	2:16-cv-16788
Georgalos vs. Sanofi S.A. et al	2:16-cv-17314
George v. Sanofi S.A. et al	2:17-cv-03585
Gibson v. Sanofi S.A. et al	2:16-cv-16784
Gilliland v. Sanofi S.A. et al	2:17-cv-00449

Matter Name	MDL Docket No.
Granderson et al v. Sanofi S.A. et al	2:16-cv-17152
Greene v. Sanofi S.A. LLC et al	2:16-cv-16748
Griggs v. Sanofi S.A. et al	2:16-cv-17064
Gross et al v. Sanofi S.A. et al	2:16-cv-15570
Gunn v. Sanofi S.A. et al	2:17-cv-03638
Harbin v. Sanofi S.A. et al	2:17-cv-00096
Harris v. Sanofi S.A. et al	2:16-cv-17145
Harris v. Sanofi S.A. et al	2:16-cv-17239
Hartley v. Sanofi S.A. et al	2:16-cv-16792
Haupt v. Sanofi S.A. et al	2:17-cv-03578
Hawkins v. Sanofi S.A. et al	2:17-cv-03380
Hawkins v. Sanofi-Aventis U.S. LLC et al	2:16-cv-16790
Herron v. Sanofi S.A. et al	2:16-cv-17092
Hershey v. Sanofi S.A. et al	2:17-cv-01170
Hiles v. Sanofi S.A. et al	2:17-cv-05379
Hitchen v. Sanofi S.A. et al	2:17-cv-05786
Hollis v. Sanofi S.A. et al	2:16-cv-17099
Hubbard v. Sanofi S.A. et al	2:17-cv-00317
Humphrey v. Sanofi S.A. et al	2:16-cv-16674
Jackson v. Sanofi S.A. et al	2:16-cv-17127
Jackson v. Sanofi S.A. et al	2:16-cv-17138
Jackson v. Sanofi S.A. et al	2:17-cv-00381
Jackson v. Sanofi S.A. et al	2:17-cv-03770
Janjanin v. Sanofi S.A. et al	2:17-cv-00885
Johnson v. Sanofi S.A.	2:16-cv-15581
Johnson v. Sanofi S.A. et al	2:16-cv-16705
Johnson v. Sanofi S.A. et al	2:16-cv-17074
Johnson v. Sanofi S.A. et al	2:16-cv-17166
Johnson v. Sanofi S.A. et al	2:16-cv-17976
Joiner v. Sanofi S.A. et al	2:16-cv-17030
Jolivet v. Sanofi-Aventis U.S., Inc. et al	2:17-cv-02297
Jones v. Sanofi S.A. et al	2:16-cv-15498
Jones v. Sanofi S.A. et al	2:16-cv-17103
Jones v. Sanofi S.A. et al	2:16-cv-17209
Justice v. Sanofi S.A. et al	2:16-cv-17186
Keys v. Sanofi S.A. et al	2:16-cv-17504
Klock v. Sanofi S.A., et al	2:16-cv-14197
Knox v. Sanofi S.A. et al	2:16-cv-16633

Matter Name	MDL Docket No.
Knox v. Sanofi S.A. et al	2:17-cv-06284
Koontz v. Sanofi S.A. et al	2:16-cv-15310
Lewis v. Sanofi S.A. et al	2:16-cv-17185
Little v. Sanofi S.A. et al	2:16-cv-17022
Long v. Sanofi S.A. et al	2:17-cv-01166
Manigault v. Sanofi S.A. et al	2:16-cv-17214
Markham v. Sanofi S.A. et al	2:17-cv-04495
Mayfield v. Sanofi SA et al	2:17-cv-00116
McCullom v. Sanofi S.A. et al	2:16-cv-17197
McCullough v. Sanofi, S.A., et al.	2:16-cv-15511
McDowell v. Sanofi S.A. et al	2:16-cv-17212
Mendoza v. Sanofi S.A. et al	2:17-cv-03397
Miniat v. Sanofi S.A. et al	2:16-cv-16686
Monger v. Sanofi S.A. LLC et al	2:16-cv-16750
Morrison v. Sanofi S.A. et al	2:16-cv-17325
Mott v. Sanofi S.A. et al	2:17-cv-03754
Mottola v. Sanofi S.A. et al	2:16-cv-15320
Nelson v. Sanofi S.A. et al	2:17-cv-05670
Newton v. Sanofi S.A. et al	2:17-cv-06288
Nicholson v. Sanofi S.A. et al	2:16-cv-16757
Norman v. Sanofi S.A., et al	2:17-cv-01603
O'Brien vs. Sanofi S.A. et al	2:16-cv-17508
Palmatier v. Sanofi S.A. et al	2:16-cv-17223
Pantalion vs. Sanofi-Aventis U.S. LLC	2:17-cv-05968
Papoulis v. Sanofi S.A. et al	2:16-cv-17207
Parkinson v. Sanofi S.A. et al	2:17-cv-00960
Patterson v. Sanofi S.A. et al	2:16-cv-17072
Paxton v. Sanofi S.A. et al	2:17-cv-05488
Payne v. Sanofi S.A. et al	2:16-cv-17200
Pearson v. Sanofi S.A. et al	2:16-cv-17840
Pelfrey v. Sanofi S.A. et al	2:16-cv-17228
Petties v. Sanofi S.A. et al	2:16-cv-17183
Phillips v. Sanofi S.A. et al	2:16-cv-15513
Pickens v. Sanofi S.A. et al	2:17-cv-05898
Pirozzoli v. Sanofi S.A. et al	2:16-cv-17191
Pradat v. Sanofi S.A. et al	2:17-cv-03752
Pryor-Lynch v. Sanofi S.A. et al	2:16-cv-17337
Randall v. Sanofi S.A. et al	2:16-cv-17511

Matter Name	MDL Docket No.
Reaves v. Sanofi S.A. et al	2:16-cv-16780
Renaud v. Sanofi S.A. et al	2:17-cv-01209
Richards et al v. Sanofi S.A. et al	2:17-cv-06289
Richardson v. Sanofi S.A. et al	2:17-cv-03430
Rieder v. Sanofi S.A. et al	2:17-cv-04824
Robertson v. Sanofi S.A. et al	2:17-cv-04839
Robinson v. Sanofi S. A. LLC et al	2:16-cv-16740
Roe v. Sanofi S A et al	2:16-cv-17943
Rogers v. Sanofi S.A. et al	2:16-cv-14486
Rome v. Sanofi S.A. et al	2:16-cv-17075
Rowe v. Sanofi S.A. et al	2:17-cv-05557
Russell v. Sanofi S.A. LLC et al	2:16-cv-17330
Santiago v. Sanofi S.A. et al	2:16-cv-16935
Santoro v. Sanofi S.A., et al	2:17-cv-02270
Sassen v. Sanofi S.A. et al	2:17-cv-06291
Scarborough v. Sanofi S.A. et al	2:17-cv-06292
Schmitz v. Sanofi S.A. et al	2:16-cv-15502
Scott v. Sanofi S.A. et al	2:16-cv-16794
Section v. Sanofi S.A. et al	2:16-cv-17147
Selders v. Sanofi S.A. et al	2:16-cv-17156
September v. Sanofi S.A. et al	2:16-cv-17227
Seymore v. Sanofi S.A. et al	2:16-cv-16795
Shea v. Sanofi S.A. et al	2:16-cv-17497
Shoemaker v. Sanofi S.A. et al	2:16-cv-17066
Shpur v. Sanofi S.A. et al	2:16-cv-17292
Shull v. Sanofi S.A. et al	2:16-cv-16687
Sibley v. Sanofi S.A. et al	2:16-cv-17035
Simmons v. Sanofi S.A. et al	2:16-cv-17496
Slade v. Sanofi S.A. et al	2:16-cv-15571
Smallman-Lloyd v. Sanofi S.A. et al	2:16-cv-17129
Smith v. Sanofi S.A. et al	2:16-cv-17162
Spann v. Sanofi S.A. et al	2:16-cv-15291
Spivey v. Sanofi S.A. et al	2:16-cv-17195
St. Ann v. Sanofi S.A. et al	2:16-cv-17179
Stallworth v. Sanofi S.A. et al	2:16-cv-17047
Steinbeiser v. Sanofi S.A. et al	2:17-cv-03403
Stevenson v. Sanofi S.A. et al	2:16-cv-17204
Stinnett v. Sanofi S.A. et al	2:16-cv-17071

Matter Name	MDL Docket No.
Stone v. Sanofi S.A. et al	2:16-cv-16798
Strickland v. Sanofi S.A. et al	2:16-cv-17067
Stuckey v. Sanofi S.A. et al	2:17-cv-05603
Sullen v. Sanofi S.A. et al	2:16-cv-17106
Summers v. Sanofi S.A. et al	2:16-cv-16805
Sykes v. Sanofi S.A. et al	2:16-cv-17043
Tarver v. Sanofi SA et al	2:17-cv-00094
Taylor v. Sanofi S.A. et al	2:17-cv-03408
Tentori v. Sanofi-Aventis U.S. LLC et al	2:17-cv-02008
Thomas v. Sanofi S.A. et al	2:16-cv-17213
Thomas v. Sanofi S.A. et al	2:16-cv-17981
Thompson v. Sanofi S.A. et al	2:16-cv-17194
Tipton v. Sanofi S.A. et al	2:16-cv-17232
Traylor v. Sanofi S.A. et al	2:16-cv-15295
Turner v. Sanofi S.A. et al	2:16-cv-17199
Vandiver v. Sanofi S.A. et al	2:17-cv-00918
Villa v. Sanofi-Aventis U.S. LLC et al	2:16-cv-17949
Walker v. Sanofi S.A. et al	2:16-cv-16032
Walker v. Sanofi S.A. et al	2:17-cv-05084
Walker vs. Sanofi S.A. et al	2:16-cv-17495
Waller v. Sanofi S.A. et al	2:16-cv-17241
Ward v. Sanofi S.A. et al	2:16-cv-17493
Wartberg v. Sanofi S.A. et al	2:16-cv-16932
Webb-McConnell v. Sanofi S.A. et al	2:16-cv-17155
Wells v. Sanofi S.A. et al	2:17-cv-06358
West v. Sanofi U.S. Services Inc. et al	2:17-cv-02067
Whitaker v. Sanofi S.A. et al	2:16-cv-17221
White v. Sanofi S.A. et al	2:17-cv-01640
White v. Sanofi S.A. et al	2:17-cv-05007
Willard v. Sanofi S.A., et al	2:16-cv-15574
Williams v. Sanofi Aventis S.A. et al	2:16-cv-17215
Williams v. Sanofi S.A. et al	2:16-cv-14479
Williams v. Sanofi S.A. et al	2:16-cv-17034
Williams v. Sanofi S.A. et al	2:16-cv-17044
Willis v. Sanofi S.A. et al	2:16-cv-17492
Wilson v. Sanofi S.A. et al	2:17-cv-06553
Wood v. Sanofi S.A. et al	2:16-cv-15321
Woodgett et al v. Sanofi SA et al	2:16-cv-15491

Matter Name	MDL Docket No.
Young v. Sanofi S.A. et al	2:16-cv-16800
Young v. Sanofi S.A. et al	2:16-cv-17235
Zenon v. Sanofi S.A. et al	2:16-cv-17175

APPENDIX E.7

PFS Not Substantially Complete (Sanofi Defendants)

Matter Name	MDL Docket No.
Abshire v. Sanofi S.A. et al	2:16-cv-17373
Adams v. Sanofi S.A. et al	2:16-cv-16299
Allen v. Sanofi S.A. et al	2:17-cv-06967
Allison v. Sanofi S.A. et al	2:17-cv-06957
Anderson v. Sanofi-Aventis U.S. LLC et al	2:16-cv-16901
Archangel v. Sanofi-Aventis U.S., Inc et al	2:16-cv-16248
Baker v. Sanofi S.A. et al	2:16-cv-17060
Ballard v. Sanofi S.A. et al	2:17-cv-00248
Baxter v. Sanofi-Aventis U.S. LLC et al	2:17-cv-01502
Bell v. Sanofi S.A. et al	2:16-cv-17108
Bell v. Sanofi S.A. et al	2:16-cv-17573
Bemiss v. Sanofi S.A. et al	2:16-cv-06425
Berge v. Sanofi S.A. et al	2:17-cv-07179
Bias v. Sanofi S.A. et al	2:16-cv-17171
Bishop v. Sanofi SA et al	2:16-cv-15579
Blancett et al v. Sanofi S.A. et al	2:17-cv-07768
Bloxton v. Sanofi S.A. et al	2:16-cv-17037
Booth v. Sanofi S.A. et al	2:17-cv-05590
Breslauer v. Sanofi S.A. et al	2:17-cv-01199
Brown v. Sanofi S.A. et al	2:16-cv-17160
Brown v. Sanofi S.A. et al	2:16-cv-17928
Brown v. Sanofi S.A. et al	2:17-cv-05427
Brown v. Sanofi S.A. et al	2:17-cv-05874
Brucker v. Sanofi S.A. et al	2:17-cv-07105
Burns v. Sanofi-Aventis U.S. LLC et al	2:16-cv-16778
Bush v. Sanofi S.A. et al	2:16-cv-17049
Butler v. Sanofi S.A. et al	2:17-cv-02135
Butlers v. Sanofi S A et al	2:16-cv-17946
Byers v. Sanofi-Aventis U.S. LLC et al	2:17-cv-00610
Carbino et al v. Sanofi-Aventis U.S. LLC et al	2:17-cv-00539
Carver v. Sanofi S.A. et al	2:16-cv-17192
Champagne v. Sanofi S.A. et al	2:16-cv-17174
Chapman v. Sanofi S.A. et al	2:17-cv-06911
Chappell v. Sanofi S.A. et al	2:16-cv-17163
Chase v. Sanofi S.A. et al	2:16-cv-15317
Chavez v. Sanofi S.A. et al	2:17-cv-07497
Cheairs v. Sanofi S.A. et al	2:17-cv-05910
Clinton v. Sanofi S.A. et al	2:16-cv-15814
Collins v. Sanofi S.A. et al	2:17-cv-05476
Cook v. Sanofi-Aventis U.S. LLC et al	2:16-cv-17980

Matter Name	MDL Docket No.
Copeland v. Sanofi S.A. et al	2:17-cv-05913
Couvillier v. Sanofi S.A. et al	2:16-cv-16938
Craddock v. Sanofi S.A. et al	2:16-cv-15572
Crawford v. Sanofi S.A. et al	2:16-cv-17151
Culpepper v. Sanofi S.A. et al	2:16-cv-17914
Daniels v. Sanofi S.A. et al	2:17-cv-05275
Daubert v. Sanofi S.A. et al	2:17-cv-07575
Daughtry v. Sanofi S.A. et al	2:16-cv-17053
Davis v. Sanofi S.A. et al	2:16-cv-16747
Davis v. Sanofi S.A. et al	2:16-cv-17985
Dean v. Sanofi S.A. et al	2:16-cv-17201
Dickerson et al v. Sanofi-Aventis U.S. LLC et al	2:16-cv-16776
Dukes v. Sanofi S.A. et al	2:16-cv-17048
Edwards-Woodard et al v. Sanofi-Aventis U.S. LLC et al	2:16-cv-16799
Eidel v. Sanofi S.A. et al	2:17-cv-06024
Ellois v. Sanofi S.A. et al	2:17-cv-03487
Encalarde v. Sanofi-Aventis, U.S., Inc. et al	2:16-cv-15863
Erkins v. Sanofi S.A. et al	2:16-cv-17131
Everett v. Sanofi S.A. et al	2:17-cv-06025
Evridge v. Sanofi S.A. et al	2:17-cv-06742
Fair v. Sanofi Aventis US Inc et al	2:16-cv-17252
Fallon et al v. Sanofi S.A. et al	2:17-cv-06271
Ferguson v. Sanofi S.A. et al	2:17-cv-03743
Fontenot v. Sanofi S.A. et al	2:17-cv-00802
Francl v. Sanofi S.A. et al	2:17-cv-07930
Francois v. Sanofi S.A. et al	2:17-cv-04811
Franklin v. Sanofi-Aventis, U.S., Inc. et al	2:16-cv-15843
Freeman v. Sanofi S.A. et al	2:17-cv-06151
Fuller et al v. Sanofi S.A. et al	2:17-cv-06194
Fultz et al v. Sanofi S.A. et al	2:17-cv-07772
Garner v. Sanofi-Aventis U.S. LLC et al	2:16-cv-16803
Garza v. Sanofi S.A. et al	2:17-cv-07206
Gibian v. Sanofi S.A. et al	2:17-cv-01800
Gibson et al v. Sanofi S.A. et al	2:17-cv-06236
Gillespie v. Sanofi S.A. et al	2:17-cv-06255
Gilliland v. Sanofi S.A. et al	2:17-cv-00449
Glaze v. Sanofi S.A. et al	2:17-cv-06238
Goeman et al v. Sanofi S.A. et al	2:17-cv-06970
Gordon v. Sanofi S. A. LLC et al	2:16-cv-16742
Gray et al v. Sanofi S.A. et al	2:17-cv-05808
Greene v. Sanofi S.A. LLC et al	2:16-cv-16748
Gregorich et al v. Sanofi S.A. et al	2:17-cv-06327
Griggs v. Sanofi S.A. et al	2:16-cv-17064
Grumet v. Sanofi S.A. et al	2:17-cv-01801

Matter Name	MDL Docket No.
Gulley v. Sanofi S.A. et al	2:17-cv-06907
Guthrie v. Sanofi S.A. et al	2:17-cv-06308
Hammond v. Sanofi S.A. et al	2:16-cv-17256
Hampton et al v. Sanofi S.A. et al	2:16-cv-17336
Hanes v. Sanofi S.A. et al	2:16-cv-15499
Harris v. Sanofi S.A. et al	2:16-cv-17239
Hartso v. Sanofi-Aventis U.S. LLC et al	2:16-cv-17984
Hartzog v. Sanofi-Aventis, U.S., Inc. et al	2:16-cv-15400
Harvey v. Sanofi S.A. et al	2:17-cv-06558
Hawkins v. Sanofi S.A. et al	2:16-cv-17188
Hawkins v. Sanofi-Aventis U.S. LLC et al	2:16-cv-16790
Haynes v. Sanofi S.A. et al	2:16-cv-17723
Helms v. Sanofi S.A. et al	2:17-cv-07774
Henderson et al v. Sanofi S.A. et al	2:17-cv-08211
Henderson v. Sanofi S.A. et al	2:17-cv-04945
Henderson v. Sanofi S.A. et al	2:17-cv-06257
Hernandez v. Sanofi-Aventis, U.S., Inc. et al	2:16-cv-15600
Higgins v. Sanofi-Aventis, U.S., Inc. et al	2:16-cv-15605
Hill v. Sanofi S.A. et al	2:17-cv-05204
Hockaday-Adams v. Sanofi S.A. et al	2:16-cv-15563
Holbrook et al v. Sanofi S.A. et al	2:17-cv-06555
Hollis v. Sanofi S.A. et al	2:16-cv-17099
Holmes v. Sanofi S.A. et al	2:17-cv-06002
Hooks et al v. Sanofi S.A. et al	2:17-cv-07917
Hoskins v. Sanofi S.A. et al	2:16-cv-17852
Howard v. Sanofi S.A. et al	2:17-cv-06016
Howard v. Sanofi S.A. et al	2:17-cv-06561
Jackson et al v. Sanofi S.A. et al	2:16-cv-16796
Jackson v. Sanofi S A et al	2:16-cv-17941
Jackson v. Sanofi S.A. et al	2:17-cv-00381
Jemmott v. Sanofi S.A. et al	2:17-cv-06624
Johnson v. Sanofi S.A.	2:16-cv-15581
Johnson v. Sanofi S.A. et al	2:16-cv-17074
Johnson v. Sanofi S.A. et al	2:17-cv-06604
Johnson v. Sanofi S.A. et al	2:17-cv-06627
Johnson v. Sanofi S.A. et al	2:17-cv-06629
Jolivette v. Sanofi-Aventis U.S., Inc. et al	2:17-cv-02297
Jones v. Sanofi S.A. et al	2:16-cv-17209
Jones v. Sanofi S.A. et al	2:17-cv-04055
Jones vs. Sanofi S.A. et al	2:16-cv-17304
Kanemaru v. Sanofi S.A. et al	2:17-cv-06031
Keys v. Sanofi S.A. et al	2:16-cv-17504
Knox v. Sanofi S.A. et al	2:17-cv-06284
Koontz v. Sanofi S.A. et al	2:16-cv-15310

Matter Name	MDL Docket No.
Kravchenko v. Sanofi S.A. et al	2:17-cv-08820
Lackey v. Sanofi S.A. et al	2:17-cv-06286
Ladner v. Sanofi S.A. et al	2:16-cv-17368
Lancien v. Sanofi S.A. et al	2:17-cv-06707
Landry v. Sanofi S.A. et al	2:17-cv-01211
Lawrence et al v. Sanofi S.A. et al	2:17-cv-06807
Leggett v. Sanofi S.A. et al	2:17-cv-06900
Leith v. Sanofi S.A. et al	2:16-cv-15286
Lester v. Sanofi S.A. et al	2:17-cv-06886
Lipman v. Sanofi S.A. et al	2:17-cv-07083
Little v. Sanofi S.A. et al	2:16-cv-17022
Lockett v. Sanofi S.A. et al	2:17-cv-07095
Long v. Sanofi-Aventis U.S. LLC et al	2:16-cv-16781
Lonzo v. Sanofi-Aventis U.S. LLC et al	2:16-cv-16793
Love v. Sanofi S.A. et al	2:17-cv-06605
Lowery v. Sanofi S.A. et al	2:17-cv-07194
Luellen-Williams v. Sanofi S.A. et al	2:17-cv-00528
Lyles v. Sanofi-Aventis U.S. LLC et al	2:16-cv-16773
Lyon v. Sanofi S.A. LLC et al	2:16-cv-16749
Lyons et al v. Sanofi S.A. et al	2:17-cv-07230
Madril v. Sanofi S.A. et al	2:17-cv-07234
Mamola v. Sanofi S.A. et al	2:17-cv-07286
Marco v. Sanofi S.A. et al	2:16-cv-16939
Markey v. Sanofi S.A. et al	2:16-cv-16934
Markham v. Sanofi S.A. et al	2:17-cv-04495
Marks v. Sanofi S.A. et al	2:17-cv-07288
Martin v. Sanofi S.A. et al	2:17-cv-05797
Matthews et al v. Sanofi S.A. et al	2:17-cv-07297
McCloud et al v. Sanofi S.A. et al	2:17-cv-07300
McCullom v. Sanofi S.A. et al	2:16-cv-17197
McCullough v. Sanofi, S.A., et al.	2:16-cv-15511
McDaniel v. Sanofi S.A. et al	2:17-cv-07719
McNeal v. Sanofi S.A. et al	2:16-cv-17919
Mead-Nothhaft v. Sanofi S.A. et al	2:17-cv-07722
Miniat v. Sanofi S.A. et al	2:16-cv-16686
Mink v. Sanofi S.A. et al	2:17-cv-02931
Mitchell v. Sanofi S.A. et al	2:16-cv-15578
Monger v. Sanofi S.A. LLC et al	2:16-cv-16750
Moore v. Sanofi-Aventis, U.S., Inc. et al	2:16-cv-15842
Morrison v. Sanofi S.A. et al	2:16-cv-17325
Mottola v. Sanofi S.A. et al	2:16-cv-15320
O'Connell v. Sanofi S.A. et al	2:17-cv-06972
Oliveri v. Sanofi S.A. et al	2:17-cv-01176
Parkinson v. Sanofi S.A. et al	2:17-cv-00960

Matter Name	MDL Docket No.
Payne v. Sanofi S.A. et al	2:16-cv-17200
Peddle v. Sanofi S.A. et al	2:16-cv-17009
Pelfrey v. Sanofi S.A. et al	2:16-cv-17228
Prince v. Sanofi-Aventis U.S. LLC et al	2:16-cv-17801
Proctor v. Sanofi S.A. et al	2:17-cv-05666
Pryor-Lynch v. Sanofi S.A. et al	2:16-cv-17337
Rasmussen v. Sanofi S.A. et al	2:17-cv-04840
Ray v. Sanofi S.A. et al	2:16-cv-17070
Reed v. Sanofi S.A. et al	2:16-cv-17843
Reynolds v. Sanofi S.A. et al	2:17-cv-08517
Richards et al v. Sanofi S.A. et al	2:17-cv-06289
Rivers v. Sanofi S.A. et al	2:17-cv-00862
Roach et al v. Sanofi S.A. et al	2:17-cv-07918
Robinson v. Sanofi S.A. et al	2:17-cv-00753
Rome v. Sanofi S.A. et al	2:16-cv-17075
Russell v. Sanofi S.A. et al	2:17-cv-00117
Russell v. Sanofi S.A. et al	2:17-cv-06728
Sassen v. Sanofi S.A. et al	2:17-cv-06291
Shaw v. Sanofi S.A. et al	2:17-cv-07777
Shea v. Sanofi S.A. et al	2:16-cv-17497
Shoemaker v. Sanofi S.A. et al	2:16-cv-17066
Shull v. Sanofi S.A. et al	2:16-cv-16687
Sibley v. Sanofi S.A. et al	2:16-cv-17035
Smith et al v. Sanofi S.A. et al	2:17-cv-06888
Smith v. Sanofi S.A. et al	2:16-cv-12943
Smith v. Sanofi S.A. et al	2:16-cv-17032
Smith v. Sanofi S.A. et al	2:16-cv-17202
Smith v. Sanofi S.A. et al	2:17-cv-00486
Smith v. Sanofi-Aventis, U.S., Inc. et al	2:16-cv-15398
Spann v. Sanofi S.A. et al	2:16-cv-15291
Spencer v. Sanofi-Aventis U.S. LLC et al	2:16-cv-17538
Spivey v. Sanofi S.A. et al	2:16-cv-17195
Stallworth v. Sanofi S.A. et al	2:16-cv-17047
Stevens v. Sanofi S.A. et al	2:17-cv-05918
Stevenson v. Sanofi S.A. et al	2:16-cv-17204
Stewart et al v. Sanofi S.A. et al	2:17-cv-07916
Stewart v. Sanofi S.A. et al	2:17-cv-06860
Stinnett v. Sanofi S.A. et al	2:16-cv-17071
Strickland v. Sanofi S.A. et al	2:16-cv-17067
Sullen v. Sanofi S.A. et al	2:16-cv-17106
Sykes v. Sanofi S.A. et al	2:16-cv-17043
Tanner v. Sanofi S.A. et al	2:17-cv-05711
Tate-Hendricks v. Sanofi S.A. et al	2:16-cv-17788
Taylor v. Sanofi S.A. et al	2:17-cv-06048

Matter Name	MDL Docket No.
Thomas v. Sanofi S.A. et al	2:16-cv-17213
Thomas v. Sanofi S.A. et al	2:16-cv-17981
Thomas v. Sanofi S.A. et al	2:17-cv-01732
Thomas v. Sanofi S.A. et al	2:17-cv-07270
Thompson v. Sanofi S.A. et al	2:16-cv-17194
Tipton v. Sanofi S.A. et al	2:16-cv-17232
Trave' v. Sanofi S.A. et al	2:17-cv-07577
Traylor v. Sanofi S.A. et al	2:16-cv-15295
Vandiver v. Sanofi S.A. et al	2:17-cv-00918
Villa v. Sanofi-Aventis U.S. LLC et al	2:16-cv-17949
Walker v. Sanofi S.A. et al	2:17-cv-05084
Waller v. Sanofi S.A. et al	2:16-cv-17241
Ward v. Sanofi S.A. et al	2:16-cv-17493
Wartberg v. Sanofi S.A. et al	2:16-cv-16932
Washington v. Sanofi S.A. et al	2:17-cv-06903
Webb v. Sanofi S.A. et al	2:17-cv-06642
Webb-McConnell v. Sanofi S.A. et al	2:16-cv-17155
Welty v. Sanofi S.A. et al	2:17-cv-06974
Werning v. Sanofi S.A. et al	2:16-cv-17169
Whitaker v. Sanofi S.A. et al	2:16-cv-17221
White v. Sanofi S.A. et al	2:16-cv-17068
Willard v. Sanofi S.A., et al	2:16-cv-15574
Williams et al v. Sanofi S.A. et al	2:16-cv-15557
Williams v. Sanofi S.A. et al	2:16-cv-17034
Williams v. Sanofi-Aventis U.S. LLC et al	2:17-cv-02194
Wilson v. Sanofi S.A. et al	2:17-cv-06553
Winkel v. Sanofi S.A. et al	2:17-cv-06659
Wittenberg vs. Sanofi S.A., et al	2:17-cv-04838
Wolfgang v. Sanofi S.A. et al	2:16-cv-16236
Wright v. Aventis Pharma S.A. et al	2:17-cv-10840
Young v. Sanofi S.A. et al	2:17-cv-05993
Zenon v. Sanofi S.A. et al	2:16-cv-17175

APPENDIX F.7

Missing PFS (505(b)(2) Defendants

Matter Name	MDL Docket No.
Crussell et al v. Sanofi S.A. et al	2:17-cv-06163
Drake v. Accord Healthcare, Inc., et al.	2:17-cv-07426
Grace v. Sandoz, et al.	2:17-cv-03716
Haldis v. Sanofi S.A. et al	2:17-cv-07458
Hatchett v. Sanofi, et al.	2:17-cv-01673
Hayden v. Sanofi S.A. et al	2:17-cv-06921
Parker v. Sanofi S.A. et al	2:17-cv-06170
Soto v. Sanofi S.A. et al	2:17-cv-06913
Strong v. Sanofi S.A. et al	2:17-cv-06908

APPENDIX G.7

Deficiency – No Response (505(b)(2) Defendants)

Matter Name	MDL Docket No.
Daniels v. Sanofi S.A., et al.	2:17-cv-05275
Davis v. Sanofi S.A., et al.	2:17-cv-05900
Pickens v. Sanofi S.A., et al.	2:17-cv-05898
Rowe v. Sanofi S.A., et al.	2:17-cv-05557

APPENDIX H.7

Substantially Deficient (505(b)(2) Defendants)

Matter Name	MDL Docket No.
Brown v. Sanofi-Aventis LLC, Sandoz Inc.	2:16-cv-18928
Snow v. Sanofi S.A., et al.	2:16-cv-16797
McConnell v. Sanofi S.A. et al.	2:16-cv-02740
DeGraff v. Sanofi S.A. et al.	2:17-cv-5457

APPENDIX I.7

Missing PFS (Sanofi Defendants)

Matter Name	MDL Docket No.
Adams, Lynette v. Sanofi SA, et al.	2:16-cv-17499
Adduci, Linda G. v. Sanofi SA, et al.	2:17-cv-06916
Albus, Cindy v. Sanofi SA, et al.	2:17-cv-07447
Basford, Patricia v. Sanofi SA, et al.	2:17-cv-06609
Belue, Deborah v. Sanofi SA, et al.	2:16-cv-17063
Bingham, Leslie v. Sanofi SA, et al.	2:16-cv-17502
Black, Alice v. Sanofi SA, et al.	2:16-cv-17206
Blair, Linda v. Sanofi SA, et al.	2:16-cv-17427
Brooks, Alnita v. Sanofi SA, et al.	2:16-cv-17433
Brown, Ada v. Sanofi SA, et al.	2:16-cv-17142
Buford, Gloria v. Sanofi SA, et al.	2:16-cv-17069
Carter, Trinette v. Sanofi SA, et al.	2:16-cv-17073
Chapman, Joyce v. Sanofi SA, et al.	2:16-cv-17217
Clark, Linda v. Sanofi SA, et al.	2:16-cv-17164
Clemons, Geneva v. Sanofi SA, et al.	2:16-cv-17059
Cole, Belinda v. Sanofi SA, et al.	2:16-cv-17945
Conley, Martha and Craig v. Sanofi SA, et al.	2:16-cv-17394
Curtis, Darlene C. v. Sanofi SA, et al.	2:17-cv-06918
Davis-Sims, Lisa v. Sanofi SA, et al.	2:16-cv-17426
Diggs, Rena v. Sanofi SA, et al.	2:16-cv-17944
Dodd, Donna and Allen v. Sanofi SA, et al.	2:16-cv-17411
Drummond, Kimberly v. Sanofi SA, et al.	2:16-cv-16942
Dumesnil, Denise v. Sanofi SA, et al.	2:17-cv-06920
Dupree, Monica v. Sanofi SA, et al.	2:16-cv-16632
Freeman, Kapreshia v. Sanofi SA, et al.	2:16-cv-17226
Giambelluca, Denise v. Sanofi SA, et al.	2:16-cv-17251
Gillum, Lacy v. Sanofi SA, et al.	2:16-cv-17170
Gomez, Sharloett v. Sanofi SA, et al.	2:17-cv-06915
Grant, Cynthia v. Sanofi SA, et al.	2:17-cv-05013
Guy, Joe Ann and Louise Guy v. Sanofi SA, et al.	2:16-cv-17669
Hammond, Wendy and Matt v. Sanofi SA, et al.	2:16-cv-17388
Harris, Gina L. v. Sanofi SA, et al.	2:17-cv-05976
Hatchett, Angela v. Sanofi SA, et al.	2:17-cv-01673
Hayden, Cynthia A. v. Sanofi SA, et al.	2:17-cv-06921

Matter Name	MDL Docket No.
Hilliard, Shirley v. Sanofi SA, et al.	2:16-cv-16933
Holloway, Angela v. Sanofi SA, et al.	2:16-cv-17178
Hughes, Kristie and David v. Sanofi SA, et al.	2:16-cv-17396
Hughes, Mary v. Sanofi SA, et al.	2:16-cv-17205
Hylton, Lela v. Sanofi SA, et al.	2:16-cv-17574
James, Marilyn v. Sanofi SA, et al.	2:17-cv-06719
Johnson, Anna v. Sanofi SA, et al.	2:16-cv-17028
King, Tammy v. Sanofi SA, et al.	2:16-cv-17418
Klapper, Maryann Walsh v. Sanofi SA et al.	2:17-cv-00484
Kyles, Pearlie v. Sanofi SA, et al.	2:16-cv-17055
Madison, Daniele v. Sanofi SA, et al.	2:16-cv-17391
Mahon, Melissa and Gary v. Sanofi SA, et al.	2:16-cv-17378
Nelson, Asha v. Sanofi SA, et al.	2:16-cv-17225
Noe, Judith v. Sanofi SA, et al.	2:16-cv-17219
Parker, Linda F. v. Sanofi SA, et al.	2:16-cv-17506
Pickett, Doris v. Sanofi SA, et al.	2:16-cv-17180
Poore, Jimmie v. Sanofi SA, et al.	2:16-cv-17505
Pope, Charlotte v. Sanofi SA, et al.	2:16-cv-17416
Powell, Dorothy v. Sanofi SA, et al.	2:16-cv-17974
Purdue, Carolyn v. Sanofi SA, et al.	2:16-cv-17230
Quick, Tracy Lynn v. Sanofi SA, et al.	2:16-cv-17582
Robbins, Sylvania v. Sanofi SA, et al.	2:16-cv-17430
Roebuck, Julieann and John v. Sanofi SA, et al.	2:16-cv-17720
Scott, Angela v. Sanofi SA, et al.	2:16-cv-17233
Semeniuk, Connie E. v. Sanofi SA, et al.	2:16-cv-17512
Shields, Christy and Brian v. Sanofi SA, et al.	2:16-cv-17752
Small, Shirley v. Sanofi SA, et al.	2:16-cv-17224
Smith, Lauri v. Sanofi SA, et al.	2:17-cv-06293
Smith, Lee A. v. Sanofi SA, et al.	2:16-cv-17489
Soto, Maria D. v. Sanofi SA, et al.	2:17-cv-06913
Starkey, Diane v. Sanofi SA, et al.	2:16-cv-15505
Strong, Frances A. v. Sanofi SA, et al.	2:17-cv-06908
Strunk, Rhonda v. Sanofi SA, et al.	2:16-cv-17234
Sullivan, Therese A. v. Sanofi SA, et al.	2:17-cv-06894
Talber, Virginia v. Sanofi SA, et al.	2:16-cv-17236
Truehill, Vanessa v. Sanofi SA, et al.	2:16-cv-17182
West, Annette v. Sanofi SA, et al.	2:16-cv-16062
Whitelow, Shirley v. Sanofi SA, et al.	2:16-cv-17412

Matter Name	MDL Docket No.
Williams, Cynthia v. Sanofi SA, et al.	2:16-cv-17222
Williamson, Cathy and Micah v. Sanofi SA, et al.	2:16-cv-17352

PFS Not Substantially Complete (Sanofi Defendants)

Matter Name	MDL Docket No.
Bice, Barbara v. Sanofi SA, et al.	2:17-cv-00751
Braswell, Carolyn v. Sanofi SA, et al.	2:16-cv-17581
Dawson, Dianne v. Sanofi SA, et al.	2:16-cv-17302
Fulcher, Jody v. Sanofi SA, et al.	2:16-cv-15855
Hays, Patsy v. Sanofi SA, et al.	2:16-cv-17540

Missing PFS (505(b)(2) Defendants

Matter Name	MDL Docket No.
Adams v. Sanofi S.A., et al.	2:16-cv-17499
Bingham v. Sanofi S.A., et al.	2:16-cv-17502
Blair v. Sanofi S.A., et al.	2:16-cv-17427
Brown v. Sanofi S.A., et al.	2:17-cv-06126
Clemons v. Sanofi S.A., et al.	2:16-cv-17059
Davis-Sims v. Sanofi S.A., et al.	2:16-cv-17426
Freeman v. Sanofi S.A., et al.	2:16-cv-17226
Freeman, et al. v. Sanofi U.S. Services Inc., et al.	2:17-cv-04019
Grace v. Sandoz Inc., et al.	2:17-cv-03716
Grant v. Sanofi S.A., et al.	2:17-cv-05013
Guy et al v. Sanofi S.A., et al.	2:16-cv-17669
Hollis v. Sanofi S.A., et al.	2:17-cv-02354
Johnson v. Sandoz Inc., et al.	2:17-cv-05566
King v. Sanofi S.A., et al.	2:16-cv-17418
Madison v. Sanofi S.A., et al.	2:16-cv-17391
McKinley v. Sanofi S.A., et al.	2:17-cv-04758
Mobley v. Sanofi S.A., et al.	2:17-cv-05358
Pope v. Sanofi S.A., et al.	2:16-cv-17416
Roebuck, et al. v. Sanofi S.A., et al.	2:16-cv-17720
Smith v. Sanofi S.A., et al.	2:17-cv-06293
Sullivan v. Sanofi S.A., et al.	2:17-cv-06894
Whitelow v. Sanofi S.A., et al.	2:16-cv-17412

Deficiency – No Response (505(b)(2) Defendants)

Matter Name	MDL Docket No.
Nixon v. Sanofi U.S. Services Inc., et al.	2:17-cv-03978

Not Substantially Complete (505(b)(2) Defendants)

Matter Name	MDL Docket No.
Adams v. Sanofi S. A., et al.	2:16-cv-16299
Beasley v. Sanofi S.A., et al.	2:17-cv-06824
Bice v. Sanofi S.A., et al.	2:17-cv-00751
Blevins v. Sanofi S.A., et al.	2:17-cv-05528
Brewer v. Sanofi S.A., et al.	2:16-cv-17313
Brown v. Sanofi-Aventis LLC, Sandoz Inc.	2:16-cv-18928
Burks v. Sanofi S.A., et al.	2:17-cv-01738
Green v. Sanofi-Aventis U. S. LLC, et al.	2:17-cv-10752
Hyter v. Sanofi S.A., et al.	2:16-cv-17326
Jackson v. Sanofi S.A., et al.	2:17-cv-07056
LaMartina v. Sanofi S.A., et al.	2:17-cv-05924
Lee v. Sanofi S.A., et al.	2:17-cv-05927
Lyles v. Sanofi-Aventis U.S. LLC, et al.	2:16-cv-16773
Morrison v. Sanofi S.A., et al.	2:16-cv-17312
Rasmussen v. Sanofi S.A., et al.	2:17-cv-04840
Stevens v. Sanofi S.A., et al.	2:17-cv-05918
Turner v. Sanofi S.A., et al.	2:17-cv-05481
Walker v. Sanofi S.A., et al.	2:17-cv-05084
Warren v. Sanofi S.A., et al.	2:17-cv-06833